Gerresheimer (ETR:GXI) has been given a €76.40 ($94.32) price target by investment analysts at JPMorgan Chase & Co. in a report released on Friday. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 10.01% from the company’s previous close.
GXI has been the subject of a number of other research reports. Kepler Capital Markets set a €65.00 ($80.25) price target on Gerresheimer and gave the company a “sell” rating in a report on Tuesday, February 6th. Hauck & Aufhaeuser set a €55.00 ($67.90) price objective on shares of Gerresheimer and gave the stock a “sell” rating in a research note on Tuesday, February 6th. Deutsche Bank set a €66.00 ($81.48) price objective on shares of Gerresheimer and gave the stock a “neutral” rating in a research note on Monday, January 22nd. Commerzbank set a €77.00 ($95.06) price objective on shares of Gerresheimer and gave the stock a “buy” rating in a research note on Monday, February 5th. Finally, equinet set a €75.00 ($92.59) price objective on shares of Gerresheimer and gave the stock a “neutral” rating in a research note on Friday, January 19th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of €70.58 ($87.14).
Shares of Gerresheimer (ETR GXI) opened at €69.45 ($85.74) on Friday. The stock has a market capitalization of $2,180.00 and a P/E ratio of 49.26. Gerresheimer has a twelve month low of €59.97 ($74.04) and a twelve month high of €78.25 ($96.60).
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/18/jpmorgan-chase-76-40-price-target.html.
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.